Abstracts tagged "Bone and inflammation"

Abstract Number: 987 • 2019 ACR/ARP Annual Meeting
Anti-citrullinated Protein Antibodies Induce Subclinical Inflammation, Bone Loss and Pain in Mice
Akilan Krishnamurthy¹, Yogan Kisten ², Alexandra Circiumaru ³, Katalin Sandor ⁴, Koji Sakurabas ⁵, Gustaf Wigerblad ⁶, Peter Damberg ⁷, Heidi Wähämaa ³, Patrik Jarvolli ⁷, Vivianne Malmström ⁸, Lars Klareskog ⁹, Camilla I Svensson ¹⁰, Juan Jimenez Jimenez Andrade ¹¹, Bence Rethi ³ and Anca Catrina ⁹, ¹Rheumatology unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Solna, Stockholm, ²Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, ⁴Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden, stockholm, Sweden, ⁵Rheumatology unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Solna, stockholm, Sweden, ⁶karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁷Karolinska Institutet, Karolinska Experimental Research and Imaging Centre (KERIC), stockholm, Sweden, stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁹Rheumatology unit Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ¹⁰Karolinska Institutet, Physiology and Pharmacology, stockholm, Sweden, Stockholm, Sweden, ¹¹Universidad Autónoma de Tamaulipas, Reynosa, Tamaulipas, Mexico, Tamaulipas, Mexico
Background/Purpose: Autoantibodies against citrullinated proteins (ACPAs) could be associated with bone loss, pain and tenosynovitis prior to disease onset in human rheumatoid arthritis (RA) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].